Compare Eli Lilly And Co (LLY) vs ProShares UltraPro QQQ ETF (TQQQ) Price & Performance

Eli Lilly (LLY) trades at $1,175.15, down 0.33% on the day, with a bullish technical signal and strong fundamental momentum. Revenue surged to $65.18B in 2025, with net income reaching $20.64B, and the company has beaten earnings estimates for three consecutive quarters. Recent news includes a lawsuit from Novo Nordisk over weight-loss drug advertising, but analyst sentiment remains overwhelmingly positive with a $1,380 consensus price target.

Outlook is supported by robust earnings growth and high profitability margins, but risks include competitive pressures and elevated valuation multiples. The stock's current price is near key resistance at $1,174, with institutional buying activity indicating continued confidence in Lilly's growth trajectory in the pharmaceutical sector.

TQQQ trades at $67.65, up 0.18% today, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The ETF's structure amplifies daily Nasdaq-100 returns, yet financial ratios are unavailable as it's a leveraged fund tracking an index. Recent news highlights volatility risks, with articles warning of amplified losses during market downturns despite historical gains in bull markets.

Outlook remains cautious due to leverage decay and bearish technicals; opportunities exist for tactical traders during rebounds, but risks include heightened volatility and structural costs. Long-term holders face potential erosion from daily rebalancing, especially in sideways or declining markets.